Deciphera CEO on tackling cancer drug resistance

December 16, 2016 Christoph Graener

 

Mike Ward, global director of content for Informa Pharma Intelligence, chats with Deciphera Pharmaceuticals’ CEO Michael Taylor about the company’s cell-signaling technology, based on a clinical pipeline of kinase inhibitors. Taylor also explains the company’s strategy of addressing drug resistance in cancer.
By simultaneously blocking multiple cancer signaling mechanisms, Deciphera believes its therapies can control drug-resistant mutations while improving therapeutic potency, durability, and selectivity. Its pipeline includes three Phase I assets and a preclinical program.



Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Michael Taylor – CEO, Deciphera Pharmaceuticals

 

Previous Video
Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology
Biotech Showcase™ 2017: ProNAI defects from oligos to DDR as Sierra Oncology

Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight glob...

Next Video
Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry
Biotech Showcase™ 2017: Chinese capital accesses Western innovation to create homegrown industry

With the Chinese market growing at 10–15% a year, it is poised to be world’s largest by 2026. Tony Chu, co-...